- Home
- AMGN vs WELL Comparison
AMGN vs WELL Comparison
Compare AMGN & WELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMGN | WELL |
|---|---|---|
| Founded | 1980 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4B | 150.1B |
| IPO Year | 2002 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AMGN | WELL |
|---|---|---|
| Price | $338.86 | $215.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $351.05 | $224.38 |
| AVG Volume (30 Days) | 2.4M | ★ 2.6M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.98% | 1.40% |
| EPS Growth | ★ 88.23 | N/A |
| EPS | ★ 3.34 | 1.02 |
| Revenue | ★ $25,424,000,000.00 | $10,838,034,000.00 |
| Revenue This Year | $5.00 | $28.56 |
| Revenue Next Year | $2.45 | $6.97 |
| P/E Ratio | ★ $100.98 | $211.04 |
| Revenue Growth | 8.83 | ★ 35.63 |
| 52 Week Low | $269.77 | $148.60 |
| 52 Week High | $391.29 | $221.68 |
Technical Indicators
Market Signals| Indicator | AMGN | WELL |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 54.17 |
| Support Level | $334.95 | $208.67 |
| Resistance Level | $346.11 | $216.39 |
| Average True Range (ATR) | 6.95 | 4.86 |
| MACD | 1.40 | -0.33 |
| Stochastic Oscillator | 81.12 | 58.32 |
Price Performance
Historical ComparisonAbout AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,800 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 900 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.